EP Patent

EP2563117B1 — Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Assigned to Salix Pharmaceuticals Ltd · Expires 2018-02-21 · 8y expired

What this patent protects

Patent listed against balsalazide-disodium.

Drugs covered by this patent

Patent Metadata

Patent number
EP2563117B1
Jurisdiction
EP
Classification
—
Expires
2018-02-21
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.